top of page
此網站是使用
.com
網站幫手設計的。立即用來製作您的網站吧！立即開始
錨點 1

VMAT2

Comparison_of_99mTc-TRODAT-1_SPECT_and_1

Apr. 2014

Comparison of 99m Tc-TRODAT-1 SPECT and 18 F-AV-133 PET Imaging in Healthy Controls and Parkinson’s Disease Patients

IT Hsiao, YH Weng, WY Lin, CJ Hsieh, SP Wey, TC Yen, MP Kung, CS Lu, and KJ Lin. 

Nuclear medicine and biology. Apr 2014. 41(4):322-9.

(99m)Tc-TRODAT-1 is the first clinical routine (99m)Tc radiopharmaceutical to evaluate dopamine neurons loss in Parkinson's disease (PD). (18)F-AV-133 is a novel PET radiotracer targeting the vesicular monoamine transporter type 2 (VMAT2) to detect monoaminergic terminal reduction in PD patients. The aim of this study is to compare both images in the same health control (HC) and PD subjects.

​

​

​

Correlation of Parkinson Disease Severit

Jun. 2014

Correlation of Parkinson Disease Severity and [18F]-FP-(+)-DTBZ Positron Emission Tomography

IT Hsiao, YH Weng, CJ Hsieh, WY Lin, SP Wey, MP, Kung, TC Yen, CS Lu, KJ Lin.

JAMA Neurology., JAMA Neurology.  2014 Jun 1;71(6):758-66.

Currently, diagnosis of Parkinson disease is mainly based on clinical criteria characterized by motor symptoms including bradykinesia, rigidity, resting tremor, and postural instability. Reliable in vivo biomarkers to monitor disease severity and reflect the underlying dopaminergic degeneration are important for future disease-modifying therapy in Parkinson disease.

​

​

​

​

Optimal scanning time window for 18F-FP-

Nov. 2011

Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.

KJ Lin, WY Lin, CJ Hsieh, YH Weng, SP Wey, CS Lu, D Skovronsky, TC Yen, CJ Chang, MP Kung, IT Hsiao*.

Nuclear Medicine and Biology. Nov 2011. 38(8):1149-1155.

18F-9-fluoropropyl-(+)-dihydrotetrabenazine (18F-AV-133) is a novel positron emission tomography tracer for imaging the vesicular monoamine transporter II in dopaminergic neuron degeneration, which might be indicative for Parkinson's disease (PD) and other parkinsonism. Studies were performed to optimize the imaging time window for calculating standardized uptake value ratio (SUVR) with correlation to distribution volume ratio (DVR) and in differentiating PD from normal controls (NCs).

  1. IT Hsiao, YT Chang, YH Weng, SW Hsu, KJ Lin, CS Lu, CC Chang. (2021). Comparisons of vesicular monoamine transporter type 2 signals in Parkinson's disease and Parkinsonism secondary to carbon monoxide poisoning. NeuroToxicology. 88. 10.1016/j.neuro.2021.11.004. 

  2. Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao IT, Yen TC, Kung MP, Wey SP, Hsu CH. [18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease. Ann Nucl Med. 2017 Aug;31(7):506-513.

  3. Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. PLoS One. 2017 Mar 3;12(3):e0173503.

  4. CY Huang, CH Liu, E T, CJ Hsieh, YH Weng, IT Hsiao, TC Yen, KJ Lin, CC Huang, Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan. Journal of the Neurological Sciences. 2015 Jun 15;353(1-2).

  5. CC Chang, IT Hsiao, SH Huang, CC Lui, TC Yen, WN Chang, CW Huang, CJ Hsieh, YY Chang, KJ Lin, 18F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism. European journal of neurology. 2015 May;22(5):845-e60.

  6. IT Hsiao, YH Weng, WY Lin, CJ Hsieh, SP Wey, TC Yen, MP Kung, CS Lu, and KJ Lin, Comparison of 99m Tc-TRODAT-1 SPECT and 18 F-AV-133 PET Imaging in Healthy Controls and Parkinson’s Disease Patients. Nuclear medicine and biology. Apr 2014. 41(4):322-9.

  7. SC Lin, KJ Lin, IT Hsiao, CJ Hsieh, WY Lin, CS Lu, SP Wey, MP Kung, TC Yen, YH Weng, In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl -(+)-dihydrotetrabenzazine PET, Journal of Nuclear Medicine. Jan 2014. 55(1):73-79.

  8. IT Hsiao, YH Weng, CJ Hsieh, WY Lin, SP Wey, MP, Kung, TC Yen, CS Lu, KJ Lin, Correlation of Parkinson Disease Severity and [18F]-FP-(+)-DTBZ Positron Emission Tomography, JAMA Neurology., JAMA Neurology.  2014 Jun 1;71(6):758-66.

  9. KJ Lin, YH Weng, CJ Hsieh, WY Lin, SP Wey, MP Kung, TC Yen, CS Lu, IT Hsiao*, Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by 18F-FP-(+)-DTBZ PET. PLOS ONE. Sep 2013. 8(9): e75952.

  10. KT Chao, HH Tsao, YH Weng, IT Hsiao, CJ Hsieh, SP Wey, TC Yen, MP Kung and KJ Lin, Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([(18) F]AV-133) in a MPTP-lesioned PD mouse model. Synapse, Sep 2012;66(9):823-31.

  11. KJ Lin, WY Lin, CJ Hsieh, YH Weng, SP Wey, CS Lu, D Skovronsky, TC Yen, CJ Chang, MP Kung, IT Hsiao*, Optimal scanning time window for (18)F-FP-(+)-DTBZ ((18)F-AV-133) summed uptake measurements. Nuclear Medicine and Biology. Nov 2011. 38(8):1149-1155.

  12. KJ Lin, YH Weng, SP Wey, IT Hsiao, CS Lu, D Skovronsky, HP Chang, MP Kung, and TC Yen, “Whole-Body Biodistribution and Radiation Dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): A Novel Vesicular Monoamine Transporter 2 Imaging Agent”, J Nucl Med. Sep 2010.51(9):1480-1485.

bottom of page